Biogen Idec and Elan submit applications for first-line use of Tysabri in anti-JCV antibody negative patients with MS Biogen Idec, 16 Jan 2013 Accessed on 21 Jan 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1774946. CommentRecommendBookmarkWatch